On August 12, Novo-Nordisk A/S declined 3.05% in regular trading, trading at $46.04/share, with turnover of $82.66 million.

On the news front, investment bank Berenberg downgraded Novo-Nordisk A/S from \"Buy\" to \"Hold\" and lowered its price target from $50 to $47. According to FactSet, the stock currently carries an average analyst rating of \"Overweight\" with a mean price target of $49.12.

The downgrade comes amid persistent market concerns over slowing GLP-1 product growth and intensifying competition from Eli Lilly. Earlier this month, Novo-Nordisk A/S reported Q2 results that beat profit expectations and raised full-year guidance, yet shares still fell approximately 6% as its next-generation CagriSema candidate lost two head-to-head trials against Eli Lilly's tirzepatide. The Berenberg downgrade adds to the cautious sentiment surrounding the stock's near-term outlook.

Within the Pharmacy sector, Eli Lilly fell 0.68%, Merck rose 0.66%, Johnson & Johnson fell 0.82%, and Pfizer fell 0.98%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)